Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis

Objective: To evaluate the cost effectiveness of etoricoxib (90mg/day) relative to celecoxib (200 or 400mg/day), and the non-selective NSAIDs naproxen (1000mg/day) and diclofenac (150 mg/day) in the initial treatment of ankylosing spondylitis (AS) from the UK NHS perspective.